Bio Essence Corp.

As of June 30, 2026, Bio Essence Corp. carries a market capitalization of 12.65M, placing it among publicly traded companies globally. Its enterprise value stands at 14.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bio Essence Corp. has 46.81M shares outstanding.

As of June 30, 2026, Bio Essence Corp. trades at a trailing price-to-earnings ratio of 7.65. The price-to-sales ratio is 3.99, and the price-to-book ratio stands at 5.40.

As of June 30, 2026, Bio Essence Corp. trades at an EV/EBITDA multiple of 8.66 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.24 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Bio Essence Corp. trades at an EV/FCF ratio of 13.20, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 14.22M versus a market cap of 12.65M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bio Essence Corp. maintains a current ratio of 0.38, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 66.94, indicating elevated leverage, while an interest coverage ratio of 1,002.89 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on invested capital (ROIC) comes in at 89.45 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 73.74, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 89.76, useful for judging operating efficiency across full business cycles. The company generates approximately 831,857.71 in revenue per employee across its workforce of 3.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Bio Essence Corp. recorded 20,250.00 in income tax expense. That works out to an effective tax rate of 1.32, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.54M, leaving 1.52M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Bio Essence Corp.'s stock has gained approximately 511.50% over the past 52 weeks. The 50-day moving average sits at 0.24, while the 200-day moving average is 0.54.

Over the twelve months ended June 30, 2026, Bio Essence Corp. generated 2.91M in revenue and converted that into 1.52M in net income, yielding earnings per share of 0.04. EBITDA reached 1.64M, while operating income came in at 1.54M.

As of June 30, 2026, Bio Essence Corp. holds 675.00 in cash and equivalents against 1.57M in total debt, resulting in a net debt position of 56,161.00. Total book value stands at 2.34M, with working capital of -998,524.00 providing operational flexibility.

Bio Essence Corp. produced 1.08M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Bio Essence Corp. posted a gross margin of 69.68, reflecting its pricing power and cost economics. The operating margin of 52.86 and net profit margin of 52.12 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 9.26, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 7.83, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bio Essence Corp. shareholders.

As of June 30, 2026, Bio Essence Corp. has an Altman Z-Score of -5.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.